PPARA and steatosis: At present, the MAFLD therapeutic targets are mainly focused on nuclear receptor agonists involved in steatosis, inflammation, or fibrogenesis, such as the farnesoid X receptor (FXR, NR1H4), peroxisome proliferator-activated receptor α (PPARα, NR1C1), as well as analogs of enterohepatic hormones, including fibroblast growth factor (FGF)19 in humans, FGF15 in rodents and FGF21 (Michelotti et al., 2013).